- Home
- NXTC vs LIXT Comparison
NXTC vs LIXT Comparison
Compare NXTC & LIXT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NXTC
- LIXT
- Stock Information
- Founded
- NXTC 2015
- LIXT 2005
- Country
- NXTC United States
- LIXT United States
- Employees
- NXTC N/A
- LIXT N/A
- Industry
- NXTC Biotechnology: Pharmaceutical Preparations
- LIXT Biotechnology: Pharmaceutical Preparations
- Sector
- NXTC Health Care
- LIXT Health Care
- Exchange
- NXTC Nasdaq
- LIXT Nasdaq
- Market Cap
- NXTC 12.8M
- LIXT 12.4M
- IPO Year
- NXTC 2019
- LIXT N/A
- Fundamental
- Price
- NXTC $5.12
- LIXT $3.59
- Analyst Decision
- NXTC Strong Buy
- LIXT
- Analyst Count
- NXTC 2
- LIXT 0
- Target Price
- NXTC $25.50
- LIXT N/A
- AVG Volume (30 Days)
- NXTC 318.4K
- LIXT 151.4K
- Earning Date
- NXTC 08-07-2025
- LIXT 08-07-2025
- Dividend Yield
- NXTC N/A
- LIXT N/A
- EPS Growth
- NXTC N/A
- LIXT N/A
- EPS
- NXTC N/A
- LIXT N/A
- Revenue
- NXTC N/A
- LIXT N/A
- Revenue This Year
- NXTC N/A
- LIXT N/A
- Revenue Next Year
- NXTC N/A
- LIXT N/A
- P/E Ratio
- NXTC N/A
- LIXT N/A
- Revenue Growth
- NXTC N/A
- LIXT N/A
- 52 Week Low
- NXTC $2.69
- LIXT $0.64
- 52 Week High
- NXTC $19.80
- LIXT $5.14
- Technical
- Relative Strength Index (RSI)
- NXTC 48.99
- LIXT 45.72
- Support Level
- NXTC $4.75
- LIXT $3.38
- Resistance Level
- NXTC $5.23
- LIXT $4.90
- Average True Range (ATR)
- NXTC 0.31
- LIXT 0.53
- MACD
- NXTC 0.02
- LIXT -0.18
- Stochastic Oscillator
- NXTC 53.28
- LIXT 11.93
About NXTC NextCure Inc.
NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include; NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer's disease.
About LIXT Lixte Biotechnology Holdings Inc.
Lixte Biotechnology Holdings Inc is a biopharmaceutical company dedicated to improving patients' lives by developing a drug class called Protein Phosphatase 2A inhibitors. Its product pipeline is focused on inhibitors of protein phosphatase 2A, used in combination with cytotoxic agents and/or x-rays, immune checkpoint blockers, and other cancer therapies. The Company believes that inhibitors of protein phosphatases have therapeutic potential for a broad range of cancers. It focuses on the clinical development of a specific protein phosphatase inhibitor, referred to as LB-100, which has been shown to have clinical anti-cancer activity at doses that produce little or no toxicity.